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Abstract
The optimal osmotic agent to treat intracranial hypertension in patients with severe traumatic 
brain injury (TBI) remains uncertain. We aimed to test whether the choice of mannitol or 
hypertonic saline (HTS) as early (first 96 hours) osmotherapy in these patients might be 
associated with a difference in mortality.  
We retrospectively analysed data from 2015 from 14 tertiary ICUs in Australia, UK and Europe 
treating severe TBI patients with intracranial pressure (ICP) monitoring, and compared 
mortality in those who received mannitol only versus HTS only.  We performed multivariable 
analysis adjusting for site and illness severity (Injury Severity Score, extended IMPACT score, 
and mean intracranial pressure over the first 96 hours) using Cox proportional hazards 
regression.
We collected data on 262 patients, and compared patients who received early osmotherapy 
with mannitol alone (n=46) with those who received HTS alone (n=46).  Mannitol patients 
were older (median age 49.2 (19.2) versus 40.5 (16.8) years, p=0.02), with higher Injury 
Severity Scores (42(15.9) versus 32.1 (11.3) p=0.001)) and IMPACT-TBI predicted 6-month 
mortality (34.5%[23-46] versus 25% [13-38] p=0.02), but had similar APACHE-II scores, and 
mean and maximum intracranial pressures over the first 96 hours.   The unadjusted hazard 
ratio for in-hospital mortality in patients receiving only mannitol was 3.35 (95% CI 1.60-7.03, 
p=0.001).  After adjustment for key mortality predictors, the hazard ratio for in-hospital 
mortality in patients receiving only mannitol was 2.64 (95% CI 0.96-7.30, p=0.06). 
The choice of early osmotherapy in severe TBI patients may affect survival, or simply reflect 
clinician beliefs about their different roles, and warrants controlled investigation.
Keywords  osmotherapy, traumatic brain injury, mannitol, hypertonic saline, mortality
Introduction
Intracranial hypertension (ICH) can be life-threatening after severe traumatic brain injury 
(TBI), yet the optimal therapeutic response remains controversial.  In particular, the role of 
hypothermia and decompressive craniectomy has been challenged by recent randomised 
controlled trials 1-3.   In contrast, osmotherapy retains an important position in the management
of ICH 4.  Two agents: mannitol and hypertonic saline (HTS), are routinely used in clinical 
practice to treat this condition.   However, consensus guidelines do not provide direction for 
the selection of a specific agent 4, 5.  Moreover, a recent systematic review has failed to resolve 
this issue, because of limited comparative studies focusing on clinical outcomes 6.  Finally, 
recent practice surveys suggest that these two options are equally commonly used 7, 8.
Given the lack of evidence-supported options for severe ICH, it seems logical to focus research 
on the optimal choice of osmotherapy.  In particular, it is now important to assess the 
epidemiology of modern osmotherapy use, including the choice of agent, the volume and timing
of administration (especially in the early phase of ICH), and any association between choice of 
agent and mortality.
Accordingly, we performed an international, retrospective, multicentre study of the 
management of severe TBI, focusing on the epidemiology of osmotherapy, and, in particular, 
the choice, volume and timing of early osmotherapy.   We aimed to test the hypothesis that the 
choice of HTS or mannitol as osmotherapy in patients with TBI and ICH might be associated 
with a difference in in-hospital mortality.  
Methods
Study design and data
We performed a retrospective study involving 14 tertiary ICUs in Australia and Europe, each 
treating a high volume of TBI patients.  Ethics approval for contribution to this international 
dataset was obtained locally by each centre.
Two centres were from Australia (both from Melbourne), 2 were from the UK (London and 
Cambridge) and the remaining 10 were from continental Europe (Paris and Nice, France; 
Valencia, Spain; Lausanne, Switzerland; Brussels, Belgium; Monza, Italy; Berlin, Germany; 
Rotterdam, The Netherlands; Solna, Sweden; Innsbruck, Austria).
Centres contributed data from severe TBI (GCS ≤ 8 post resuscitation) patients in 2015 with an 
intracranial pressure (ICP) monitor in-situ, up to a maximum of 20 patients per centre. Eligible 
patients were of at least 18 years of age, with either an isolated severe TBI or severe TBI as part
of multi-trauma, and had an ICP monitor for at least 96 hours.  Baseline demographic data [age, 
indicators of TBI severity (neurological and vital signs pre-hospital and on hospital arrival, 
initial CT scan findings as summarized by the Marshall score, mean ICPs over the first 96 
hours), and illness severity scores [APACHE-II, Injury Severity Scores (ISS))] were collected for 
each patient.  An extended IMPACT score (core + CT + lab) - a prognostic tool of 6-month 
outcome post moderate and severe TBI 9- was calculated for each patient.
Six-hourly ICPs, as recorded from the extra-ventricular drain (EVD) or intraparenchymal 
catheter, as well as aspects of neuro-intensive care management were recorded for all patients. 
Data were collected for up to 7 days from ICU admission, or until the ICP monitor was removed,
whichever came first.
Outcome data included in-hospital mortality, length of ICU and hospital stay, and days alive and
free from ICU at 30 days and days alive and free from hospital at 60 days. Those patients who 
received osmotherapy with mannitol only or HTS only during the first 96 hours of their ICU 
stay were compared with regards to mortality.  Groups were separated in this way to avoid the 
confounding effect of exposure to both agents.  This time cut-off was chosen because, as 
previously reported, most episodes of osmotherapy treatment in severe TBI patients take place
during this period 10.
In order to standardise the different volumes and concentrations of HTS and mannitol 
delivered, we calculated the osmotic load.  For example, 100 mL of 3% NaCl (1027 mOsm/L) 
has a roughly equivalent osmotic load to 100 mL of 20% mannitol (1100 mOsm/L), both being 
about 100 mOsm.
Statistical analysis
All data were initially assessed for normality. Group comparisons were performed using chi-
square tests for equal proportion, student t-tests for normally distributed data and Wilcoxon 
rank-sum tests otherwise, with results reported as n (%), mean (standard deviation) or median
(interquartile range) respectively. 
The primary outcome (hospital mortality) was analysed using Cox-Proportional Hazards 
regression. To account for known predictors of outcome and potential heterogeneity between 
sites, multivariable regression was performed adjusting for Injury Severity Score (ISS), 
extended IMPACT (core + lab + CT) score, mean ICP over the first 96 hours and centre, with the 
latter treated as a random effect. 
To further account for baseline imbalance between mannitol and HTS groups, propensity 
adjusted sensitivity analysis was performed. Using multivariable logistic regression with 
exclusive mannitol usage as the outcome, a model was derived to create the probability 
(propensity) that each patient would receive mannitol. This model was developed using both 
stepwise selection and backward elimination techniques, incorporating only variables that had 
a p-value < 0.2 for both techniques. Baseline variables considered for model inclusion were age,
gender, APACHE II score, Injury Severity Score and neurosurgery for clot evacuation. Each 
patient’s propensity to receive mannitol was then included as a covariate in the multivariable 
models in conjunction with treatment, extended IMPACT score, mean ICP over the first 96 
hours and centre (random effect).  Time to event between the two groups was presented using 
Kaplan Meier curves with comparison using log-rank tests.
All analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) and a two-
sided p-value of 0.05 was used to indicate statistical significance.
Results
Patient selection
We collected data on 262 consecutive patients.  We excluded patients who died within the first 
96 hours, as well as those who did not receive osmotherapy during this period.  Moreover, we 
excluded patients who were exposed to both mannitol and HTS during the study period.  
Accordingly, 46 patients received mannitol only and 46 patients received HTS only during this 
period (Figure 1).
(Figure 1 - Flow Chart)
The characteristics of the two osmotherapy groups are shown in Table 1.  In comparison, 
patients who received no early osmotherapy whatsoever had similar ISS, APACHE II scores and 
extended IMPACT scores, but lower daily maximum ICPs than those who received osmotherapy
(see eTable 1, supplementary appendix).
(Table 1)
Patients were predominantly young to middle-aged males in both groups, with a significantly 
older age in those treated with mannitol.  Furthermore, illness severity scores (ISS, APACHE-II 
scores, extended IMPACT scores) indicated greater severity in those patients treated with 
mannitol.  Finally, while more patients in the mannitol group had neurosurgery for clot 
evacuation, there was no difference in the rates of decompressive craniectomy or extra-
ventricular drainage of CSF.  
Hypothermia and barbiturate coma were used in similar amounts in both groups (see Table 1). 
Moreover, propofol was used in a greater percentage of patients treated with HTS.  
Importantly, mean and maximum intracranial pressures over the first 96 hours were similar in 
the two groups (see Figure 2).   
(Figure 2- mean ICP)
Osmotherapy
All 14 centres used osmotherapy in certain patients within the study time window.  However, 
two centres used only HTS, two centres used only mannitol, and 10 centres used a combination 
of both.   Each centre contributed a median of 3 [IQR 0-5] patients to the HTS group, and 3 [IQR 
0-5] patients to the mannitol group. 
HTS concentration varied by centre,  however each centre used only one HTS concentration.  
The range of HTS concentrations included 3% (n = 3), 5% (n = 2), 7% (n= 1 ), 7.5% (n = 3), 10%
(n = 2) and 23.5% NaCl (n = 1).   Approximately half of the HTS group received osmotherapy on 
any given day, as described in Table 2, for a median total osmotic load of 629 [322-965] mOsm 
during the first 96 hours.
20% mannitol was the formulation used in the 11 centres using mannitol, while one centre 
used 15% mannitol.   Mannitol use was greatest on the first day, whereas it was less commonly 
used for the remainder of the week, with approximately a quarter of patients receiving such 
therapy on any given day.  Patients received a median total osmotic load of 447[238-745]
mOsm of mannitol during the first 96 hours.  Hence, patients in the HTS group received a larger 
median osmotic load than those in the mannitol group (see Table 2).
(Table 2)
Outcomes
Patients receiving mannitol only, were 3 times more likely to die in hospital than patients 
receiving HTS only (Hazard Ratio (95%CI) 3.35 (1.60-7.03) p=0.001). However, after 
accounting for adjustment for centre, ISS, extended IMPACT and mean ICP over the first 96 
hours, this result no longer retained statistical significance (Hazard Ratio (95% CI) 2.64 (0.96-
7.30) p=0.06) (Table 3).  
When the multivariable analysis of time to death was additionally adjusted for each patient’s 
probability (propensity) to receive mannitol, the increased risk in death for mannitol patients 
remained non-significant (Hazard Ratio (95%CI) 2.52 (0.90-7.06) p=0.08) (eTables 2 and 3).
(Table 3)
Table 4 summarises unadjusted hospital and ICU mortality, days alive and free from ICU to 30 
days, and days alive and free from hospital to 60 days, censored at hospital discharge, 
according to osmotherapy. Hospital mortality was more than twice as great in the mannitol-
only group, while unadjusted ICU mortality was three times greater in this group.  Consistent 
with these findings, the number of days alive and free from ICU and hospital was also greater in





We performed an international observational, multicentre study of patients with severe 
traumatic brain injury, intracranial pressure monitoring and intracranial hypertension. We 
assessed the epidemiology of osmotherapy use, with focus on the choice, volume and timing of 
early osmotherapy, and aimed to test the hypothesis that the exclusive use of mannitol or HTS 
would be associated with a difference in mortality. We found that patients treated with 
mannitol were more severely injured. Moreover, we found that, in such mannitol-treated 
patients, on unadjusted comparison, both ICU and hospital mortality were significantly higher.  
Importantly, we observed that the two agents were used differently in terms of timing, with 
mannitol being used predominantly on the first day of a patient’s stay, whereas HTS was 
administered on multiple days.  Finally, we found that after adjustment for several key markers 
of illness severity and propensity to receive mannitol, the use of mannitol was associated with 
an approximate 2.5-fold, but statistically non-significant (p=0.06), point estimate  for an 
increased risk of death.   
Relationship to previous studies
To our knowledge, no previous studies have described the epidemiology of osmotherapy use 
across multiple neurotrauma centres in different countries.   In 2016, a systematic review of 
randomised controlled trials (RCTs) comparing HTS and mannitol concluded that HTS led to 
fewer failures to control ICP than mannitol, but that studies had been underpowered to detect a
significant mortality difference6.  Moreover, the possible impact of osmotherapy choice on 
mortality has been assessed only as a secondary outcome in three of the six studies comparing 
these two types of osmotherapy.   These three studies (9-11), reported mortality at variable 
time points ranging from in-hospital to 90 days or 6 months.  However, illness severity scores 
were reported in only one study 11 and treatment with craniotomy, cooling or barbiturate coma 
were only reported in another 12.  The aggregate mortality from these 3 RCTs was 16 of 50 
patients (32%) treated with HTS, versus 21 of 55 patients (38%) treated with mannitol.   In 
summary, prospective studies so far looking at this question have been limited by small 
numbers, the fact that mortality was a secondary outcome, and by incomplete reporting of 
other key therapies.
Implications of study findings
Our study implies that mannitol and HTS are currently used as the sole osmotherapy agent in 
similar percentages in the early management of severe TBI across multiple centres in Europe, 
UK and Australia.  Daily patterns of osmotherapy administration differed markedly between 
the two osmotherapy groups, with mannitol being administered largely on the first day of ICU 
stay, and HTS being used more consistently on each day, implying different clinician beliefs 
about the differing role and effects of the two osmotic agents.  This differential prescribing does
not appear to be explained by osmotherapy being given prior to emergency neurosurgery, with 
similar numbers of patients operated on in each group (23 patients in HTS group versus 27 
patients in the mannitol arm).  Furthermore, while only one concentration of mannitol was 
used (20%) in almost all centres, large variation in HTS concentrations existed (from 3% to 
23.5%), implying the need to be specific when referring to HTS therapy and that there is no 
consensus regarding the optimal concentration to be used. Our results imply that mannitol may
be given more frequently to patients with greater TBI severity, leading to a strong unadjusted 
association between its administration and mortality. Finally, the observation that, after 
adjustment for multiple markers of illness severity, mannitol remains a nearly-significant 
predictive variable for mortality with a nearly 2.5-fold point estimate for an increase in the risk 
of death is striking.  One possible explanation is that the choice of osmotherapy affects 
mortality.  However, another possible explanation, given important differences between 
groups, is that this finding simply reflects differences in clinicians’ beliefs about the role and 
effects of these two agents, incompletely accounted for by multivariate analysis.  This requires 
further investigation in controlled trials.
Strengths and limitations
Our study has several strengths.  First, we included multiple centres from many countries, 
thereby increasing the external validity of our observations.   Second, we provided detailed 
information on the dose, timing and concentration of the osmotherapy used, thus enabling 
clinicians to relate such interventions to their practice.  Third, we focused on the early phase of 
intervention with osmotherapy, where such intervention is most likely to have impact, thus 
maximising our ability to see a difference if one exists.  Fourth, we only compared patients 
where treatment was limited to one agent or the other, thereby removing the confounding 
effects of exposure to both agents.  Moreover, we accounted for differences in baseline illness 
severity using several established and validated predictive scores (APACHE-II, IMPACT, ISS) as 
well as other important elements of management, thus attenuating the effect of confounding on 
the relationship between osmotherapy and mortality. 
Our study, however, has some limitations.  It was not a randomised controlled trial, and any 
association, unadjusted or adjusted, cannot be used to infer causality.  Despite adjustment for 
multiple measures of illness severity, we may have failed to detect baseline differences 
between the patients, and it remains possible that mannitol use may have simply been a 
marker for greater clinician concern.  Since mannitol use was predominantly on the first day 
after injury (compared to the hypertonic saline group where the requirement for osmotherapy 
was in later days), this early intracranial hypertension may also reflect an unmeasured 
difference between groups in patients’ primary or secondary brain injury severity.  Adjustment 
cannot account for unmeasured differences. 
Of note, this is the first international, multicentre study to provide information on the 
association between osmotherapy choice and mortality, a key patient-centred outcome, which 
has previously not been formally assessed as primary outcome for osmotherapy in TBI 
patients.  However, exact triggers for osmotherapy use were not recorded, meaning that we 
cannot differentiate between osmotherapy use as prophylaxis and treatment, nor determine 
whether clinicians may have used these two agents in different ways.  Lack of follow-up of 
neurological outcome in survivors precludes any comments on whether the lower mortality in 
the HTS patients translated into meaningful long-term recovery. Moreover, lack of precise 
information about the causes of death precludes speculation about possible mechanisms of 
mannitol toxicity, if indeed any such toxicity exists.   Of note, nephrotoxicity associated with 
mannitol exposure in neurosurgery and stroke patients 13, 14 has been described and an animal 
model of TBI has suggested that inflammation and apoptosis may be substantially lower with 
HTS than mannitol 15.  
Our study did not report on osmotherapy use in North American centres or developing 
countries, and we cannot comment on osmotherapy use in such settings.  Finally, we do not 
have information about osmotherapy use prior to ICU admission; however, this has seldom 
been reported in studies of critical care osmotherapy use.
Conclusion
In conclusion, in an international, multicentre, observational study of early osmotherapy in 
patients with severe traumatic brain injury, intracranial pressure monitoring and intracranial 
hypertension, we found that the exclusive use of mannitol and HTS was similar but also that 
patients treated with mannitol appeared to be more severely ill and that their unadjusted in-
hospital mortality was significantly greater. After adjustment for several markers of illness 
severity, mannitol use remained associated with a 2.5-fold point-estimate for an increase in 
risk of death.  This point-estimate was not significant. Our findings raise the possibility that 
choice of osmotherapy agents in severe TBI patients may affect survival, or alternatively simply
reflect major differences in clinician beliefs about their different roles, and suggest the need for 
controlled investigation of osmotherapy agents in this population.
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Table 1: Comparison of baseline characteristics, injury severity and treatments of 
patients receiving HTS only versus mannitol only in the first 96 hours of ICU stay




Age in years 40.5 (16.8) 49.2 (19.2) 0.02
Male sex, % (n) 71.7% (33) 76.1% (35) 0.64
SEVERITY OF INJURY
GCS (post resuscitation, pre-intubation) 5 [3-7] 5 [3-9] 0.30
Marshall Score 3 [2-5] 4 [3-5] 0.02
Injury Severity Score 32.1 (11.3) 42 (15.9) 0.001
APACHE II 20 [15-23] 22 [17-32] 0.1
Extended IMPACT predicted 6-month % 
mortality
25 [13-38] 34.5 [23-46] 0.02
Mean ICP over first 96 hours, mmHg 13.4 (4.3) 13.8 (5.2) 0.69

















Maximum ICP in the first 96 hours, mmHg 22.7 (7.4) 26.4  (15.9) 0.16
TREATMENTS
Neurosurgery for clot evacuation, % (n) 26.1% (12) 47.2% (17) 0.05
Decompressive craniectomy, % (n) 23.9% (11) 21.7% (10) 0.80
Day of decompressive craniectomy 1 [0-2] 1 [0-2] 0.78
Extraventricular CSF drainage, %(n) 45.7% (21) 43.5% (20) 0.83
Serum Na+,  mmol/L
Day 0 
Day 1































Sedation with propofol, % (n)
Sedation with opioid, % (n)










Barbiturate coma, % (n) 13% (6) 19.6% (9) 0.40
Hypothermia < 35°C at any point, % (n) 39% (18) 30% (14) 0.38
1
CSF=cerebrospinal fluid, CT= computed tomography, HTS=hypertonic saline, ICP=intracranial pressure, 
ICU=Intensive Care Unit, IMPACT=International Mission for Prognosis and Analysis of Clinical Trials in 
Traumatic brain injury, TBI=traumatic brain injury.    
Values are presented as mean (standard deviation) or median [interquartile range]
Sedation with propofol/opioid/midazolam refers to any use of these agents in isolation or combination 
during the first 96 hours.
Figure 2
A comparison of mean intracranial pressure over time between the two groups














Intracranial pressure over time
Mannitol
HTS
ICP = intracranial pressure
HTS = hypertonic saline
Values presented are mean ± standard deviation
2
Table 2:  Osmotic load administered by day of treatment
Hypertonic saline (3%-23.5%)













Day 0 26      325 [189-624] 35          275 [220-549]
Day 1 24       342 [171-643] 11 281 [220-549]
Day 2 23       257 [171-449] 13 384 [137-549]
Day 3 15       342 [217-513] 10 275 [171-412]
p-value = 0.09 for total osmotic load between groups over first 96 hours
n =number of patients receiving osmotherapy on a given day
median and interquartile range of osmotic load are presented
* Osmotic load = total daily mOsm given  
100 mL of 3% NaCl (1027 mOsm/L) has a roughly equivalent osmotic load to 100 mL of 
20% mannitol (1100 mOsm/L) 
3










Mannitol 3.35 (1.60-7.03) 0.001 2.64 (0.96-7.30) 0.06
Injury Severity Score 1.05 (1.03-1.07) <0.0001 1.04 (1.01-1.06) 0.008
Extended IMPACT Score 1.03 (1.01-1.05) 0.006 1.04 (1.01-1.06) 0.002
Mean ICP over first 96 hours 1.09 (1.01-1.18) 0.03 1.12 (1.03-1.22) 0.008
Hierarchical analysis adjusted for centre, Injury Severity Score, Extended IMPACT score, and mean ICP over the 
first 96 hours
Hazard ratios are calculated using mannitol as a categorical variable, and for 1 point increase in Injury Severity 
Score, Extended IMPACT Score, and 1 mmHg increase in mean ICP over the first 96 hours
ICP=intracranial pressure, IMPACT=International Mission for Prognosis and Analysis of Clinical Trials in 
Traumatic Brain Injury
Table 4- Unadjusted hospital and ICU mortality and days alive and free from ICU or hospital 






Hospital Mortality % (n) 21.7% (10) 52.2% (24) 0.002
ICU Mortality % (n) 15.2% (7) 47.8% (22) 0.001
Days Alive & Free from ICU at 30 days 13.4 [5-18] 0 [0-13.3] 0.004
Days Alive & Free from Hospital at 60 days 25 [0-37.3] 0 [0-5.5] 0.16
HTS= hypertonic saline
Data are presented as percentage (n) or median [interquartile range]
4
Figure 3. A Kaplan-Meier survival plot (unadjusted) by osmotherapy agent, censored at 
hospital discharge or 30 days
5
Supplementary appendix
eTable 1: Comparison of baseline characteristics, injury severity, treatments and 
outcomes of patients receiving HTS only, mannitol only and both mannitol and HTS 








HTS and mannitol 
(n=46)
CHARACTERISTICS
Age, years 45.9 (20.1) 40.5 (16.8) 49.2 (19.2) 46.5 (19.6)
Male sex, % (n) 79.6% (90) 71.7% (33) 76.1% (35) 73.9% (34)
SEVERITY OF INJURY
GCS (post resuscitation, pre-
intubation)
7 [5-7] 5 [3-7] 5 [3-9] 4 [3-8]
Injury Severity Score 32.3 (12.3) 32.1 (11.3) 42 (15.9) 27 [25-34]
APACHE II 20.5 (11.1) 20 [15-23] 22 [17-32] 21 [16-25]
Extended IMPACT predicted, 
% mortality
24 (16.6) 25 [13-38] 34.5 [23-46] 25 [13-43]
Mean ICP over first 96 hours,
mmHg
10.2 (4.4) 13.4 (4.3) 13.8 (5.2) 16 (5.0)





















Maximum ICP in the first 96 
hours, mmHg
18.3 (7.1) 22.7 (7.4) 26.4  (15.9) 25.7 (9.3)
TREATMENTS
Neurosurgery for clot 
evacuation, % (n)
34.9% (37) 26.1% (12) 47.2% (17) 26.1% (12)
Decompressive craniectomy, 
% (n)
12.4% (14) 23.9% (11) 21.7% (10) 32.6 % (15)
Day from ICU admission to 
decompressive craniectomy
0 [0-1] 1 [0-2] 1 [0-2] 1 [1-4]
Extraventricular CSF 
drainage, %(n)













































Barbiturate coma, % (n) 2.7% (3) 13% (6) 19.6% (9) 15.5% (7)
Hypothermia < 35°C at any 
point, % (n)








HTS and mannitol 
(n=46)
OUTCOMES
ICU LOS, days 17 (15.1) 16.1 (8.06) 16.5 (15) 20.5 (13.6)
Hospital LOS, days 21 [14.5-33] 25 [17-39] 13.5 [8.08-25] 23.8 [16-46]
ICU Mortality, % (n) 15% (17) 15.2% (7) 47.8% (22) 21.7% (10)
Hospital Mortality, % (n) 18.6% (21) 21.7% (10) 52.2% (24) 21.7% (10)
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APACHE II score 1.03 (1.00-1.06) 0.06 1.03 (0.99-1.06) 0.13
Age 1.03 (1.00-1.05) 0.03 1.04 (1.01-1.06) 0.009
Injury Severity 
Score 1.06 (1.02-1.09) 0.002 1.07 (1.02-1.11) 0.002
OR are calculated for each 1 point increase in APACHE II score, 1 year increase in age, and 1 point increase in Injury 
Severity Score








Mannitol 3.35 (1.60-7.03) 0.001 2.52 (0.90-7.06) 0.08
Propensity to receive mannitol 1.04 (1.02-1.05) <0.0001 1.03 (1.01-1.06) 0.002
Extended IMPACT Score 1.03 (1.01-1.05) 0.006 1.02 (1.00-1.05) 0.07
Mean ICP over first 96 hours 1.09 (1.01-1.18) 0.03 1.11 (1.03-1.21) 0.01
To account for potential heterogeneity between locations, site was further included as a random effect.
Hazard ratios are calculated using mannitol as a categorical variable, and each 1 point increase in Extended IMPACT 
Score, and 1 mmHg increase in mean ICP
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